2016年<\/span>全球有超19億成年人超重（定義為身體質量指數（BMI）≥25^{2<\/sup>），其中超6.5億人為肥胖（定義為BMI≥30^{3<\/sup>）。世界肥胖聯合會預測，到2025年，可能有27億成年人超重或肥胖，這將成為全球健康挑戰，也給個人、醫療保健系統和社會帶來沉重的負擔。超重和肥胖是復雜的慢性疾病，涉及異常或過多的脂肪堆積，可對個人的整體健康構成風險。^{4<\/sup><\/p> \n}}}

Survodutide 是一種GCGR\/GLP-1R雙重激動劑，可同時激活胰高血糖素樣肽-1（ GLP-1 ）受體和胰高血糖素（GCG）受體，這對于控制代謝功能至關重要^{5<\/sup>。在另一項II期研究中評估了survodutide對NASH和肝纖維化（F1\/F2\/F3期）成人患者（無論是否患有2型糖尿病）的治療效果^{6<\/sup>，該研究獲得了美國FDA的快速通道認定^{7<\/sup>。Survodutide由勃林格殷格翰和Zealand Pharma聯合開發，是勃林格殷格翰在代謝心腎疾病領域研發組合的組成部分。<\/p> \n}}}

勃林格殷格翰致力于研究突破性療法，旨在變革生命，守護世世代代的健康。作為一家研發驅動的全球領先生物制藥企業，公司在醫療需求高度未得到滿足的領域通過創新展現價值。勃林格殷格翰自1885年成立以來一直是一家獨立的家族企業，始終著眼長遠與可持續發展。在人用藥品、動物保健兩大業務領域，全球有超過5.3萬名員工服務逾130個地區。更多詳情，請訪問：www.boehringer-ingelheim.com<\/a><\/p> \n

\n \n \n \n \n \n \n \n \n \n
<optgroup id="kgssg"></optgroup>
<center id="kgssg"></center>
久久久亚洲欧洲日产国码二区
1.Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906). Available at https:\/\/www.boehringer-ingelheim.com\/human-health\/metabolic-diseases\/obesity\/phase-ii-clinical-trial-weight-loss-results.<\/span><\/p> <\/td> \n <\/tr> \n
2.World Health Organization. Obesity and Overweight. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed June 2023.<\/span><\/p> <\/td> \n <\/tr> \n
3.World Heart Federation. Obesity. 2015. Available at: https:\/\/world-heart-federation.org\/what-we-do\/obesity\/#:~:text=Global%20estimates%20suggest%20that%20almost,overweight%20or%20obesity%20by%202025 . Accessed June 2023.<\/span><\/p> <\/td> \n <\/tr> \n
4.Bray GA et al. Obesity: A chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev 2017;18:715–723.<\/span><\/p> <\/td> \n <\/tr> \n
5.T. Zimmerman et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy. Molecular Metabolism. 2022;66:101633.<\/span><\/p> <\/td> \n <\/tr> \n
6.ClinicalTrials.gov: A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3). Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04771273https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04771273 Accessed June 2023.<\/span><\/p> <\/td> \n <\/tr> \n
7.Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH. https:\/\/www.boehringer-ingelheim.com\/us\/press-release\/boehringer-ingelheim-and-zealand-pharma-receive-fda-fast-track-designation. Accessed June 2023.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p>"]; $("#dvExtra").html(content_array[0]);})();
<center id="kgssg"></center>